Trials / Completed
CompletedNCT06836037
A Clinical Study of Efinopegdutide (MK-6024) in Healthy Chinese Volunteers (MK-6024-011)
A Single and Multiple Dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics of MK-6024 in Healthy Chinese Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 56 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 20 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
The goal of this study is to learn about the safety and whether people tolerate a study medicine called efinopegdutide. The study will also measure what happens to efinopegdutide in a healthy person's body over time.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Efinopegdutide | Subcutaneous injection |
| DRUG | Placebo | placebo matching efinopegdutide |
Timeline
- Start date
- 2022-09-05
- Primary completion
- 2023-02-02
- Completion
- 2023-02-02
- First posted
- 2025-02-20
- Last updated
- 2025-02-21
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06836037. Inclusion in this directory is not an endorsement.